Clinical correlates of vitamin D deficiency in established psychosis

BMC Psychiatry

Volumn 16, Issue 1, 2016, Pages

  Lally, J ^a,b   Gardner Sood, P ^a   Firdosi, M ^b   Iyegbe, C ^a   Stubbs, B ^a,b   Greenwood, K ^c   Murray, R ^b   Smith, S ^b   Howes, O ^a,d   Gaughran, F ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular; Metabolic syndrome; Psychosis; Schizophrenia; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; 25-HYDROXYVITAMIN D; CHOLESTEROL; VITAMIN D;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; METABOLIC SYNDROME X; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; WAIST CIRCUMFERENCE; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; COMORBIDITY; ENGLAND; PREVALENCE; PSYCHOTIC DISORDERS;

ADULT; CARDIOVASCULAR DISEASES; CHOLESTEROL; COMORBIDITY; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; PREVALENCE; PSYCHOTIC DISORDERS; RISK FACTORS; TRIGLYCERIDES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84962460769     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-016-0780-2     Document Type: Article

References (49)

1. Berk M, Jacka FN, Williams LJ, Ng F, Dodd S, Pasco JA. Is this D vitamin to worry about? Vitamin D insufficiency in an inpatient sample. Aust N Z J Psychiatry. 2008;42(10):874-8.
2. Menkes DB, Lancaster K, Grant M, Marsh RW, Dean P, du Toit SA. Vitamin D status of psychiatric inpatients in New Zealand's Waikato region. BMC Psychiatry. 2012;12:68.
3. Crews M, Lally J, Gardner-Sood P, Howes O, Bonaccorso S, Smith S, Murray RM, Di Forti M, Gaughran F. Vitamin D deficiency in first episode psychosis: A case-control study. Schizophr Res. 2013;150(2-3):533-7.
4. Cutillas-Marco E, Fuertes-Prosper A, Grant WB, Morales-Suarez-Varela M. Vitamin D deficiency in South Europe: effect of smoking and aging. Photodermatol Photoimmunol Photomed. 2012;28(3):159-61.
5. Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, Cooper JD, Dastani Z, Li R, Houston DK, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med. 2013;10(2):1-13.
6. Liu L, Chen M, Hankins SR, Nunez AE, Watson RA, Weinstock PJ, Newschaffer CJ, Eisen HJ. Serum 25-hydroxyvitamin D concentration and mortality from heart failure and cardiovascular disease, and premature mortality from all-cause in United States adults. Am J Cardiol. 2012;110(6):834-9.
7. Lindqvist PG, Olsson H, Landin-Olsson M. Are active sun exposure habits related to lowering risk of type 2 diabetes mellitus in women, a prospective cohort study? Diabetes Res Clin Pract. 2010;90(1):109-14.
8. Lindqvist PG. Cardiology Patient Page. On the possible link between vitamin D deficiency and cardiovascular disease: should we D-lighten our lives? Circulation. 2014;129(13):e413-4.
9. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand. 2015;132(2):144-57. n/a-n/a.
10. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU. : Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015 (in press).
11. Gardner-Sood P, Lally J, Smith S, Atakan Z, Ismail K, Greenwood KE, Keen A, O'Brien C, Onagbesan O, Fung C, et al. Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. Psychol Med. 2015;45(12):1-11.
12. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ. 2013;346:f2539.
13. Tiwari S, Pratyush DD, Gupta SK, Singh SK. Vitamin D deficiency is associated with inflammatory cytokine concentrations in patients with diabetic foot infection. Br J Nutr. 2014;112(12):1938-43.
14. Zhu DM, Liu Y, Zhang AG, Chu ZX, Wu Q, Li H, Ge JF, Dong Y, Zhu P. High levels of vitamin D in relation to reduced risk of schizophrenia with elevated C-reactive protein. Psychiatry Res. 2015;228(3):565-70.
15. Berg AO, Melle I, Torjesen PA, Lien L, Hauff E, Andreassen OA. A cross-sectional study of vitamin D deficiency among immigrants and Norwegians with psychosis compared to the general population. J Clin Psychiatry. 2010;71(12):1598-604.
16. Humble MB, Gustafsson S, Bejerot S. Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric out-patients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis. J Steroid Biochem Mol Biol. 2010;121(1-2):467-70.
17. Itzhaky D, Amital D, Gorden K, Bogomolni A, Arnson Y, Amital H. Low serum Vitamin D concentrations in patients with schizophrenia. Isr Med Assoc J. 2012;14(2):88-92.
18. Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, Khan H, Baena CP, Prabhakaran D, Hoshen MB, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ. 2014;348:g1903.
19. Walker E, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334-41.
20. Gaughran F, Stahl D, Ismail K, Atakan Z, Lally J, Gardner-Sood P, Patel A, David A, Hopkins D, Harries B, et al. Improving physical health and reducing substance use in psychosis -- randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial. BMC Psychiatry. 2013;13(1):263.
21. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989;7:59-67.
22. American Psychiatric Association. Multiaxial assessment. In: Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revised) (DSM-IV-TR). USA: APA; 2002.
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
24. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands). 1990;16(3):199-208.
25. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med. 1989;12(2):159-82.
26. Saunders JB, Aasland OG, Babor TF, DeLaFuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption - II. Addiction. 1993;88:617-29.
27. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381-95.
28. Soundy A, Roskell C, Stubbs B, Vancampfort D. Selection, use and psychometric properties of physical activity measures to assess individuals with severe mental illness: a narrative synthesis. Arch Psychiatr Nurs. 2014;28(2):135-51.
29. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. BMJ. 2010;11(340):142-7.
30. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet. 2005;366(9491):1059-62.
31. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-11.
32. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690-3.
33. Suvisaari J, Loo BM, Saarni SE, Haukka J, Perala J, Saarni SI, Viertio S, Partti K, Lonnqvist J, Jula A. Inflammation in psychotic disorders: a population-based study. Psychiatry Res. 2011;189(2):305-11.
34. De Berardis D, Conti CM, Campanella D, Carano A, Scali M, Valchera A, Serroni N, Pizzorno AM, D'Albenzio A, Fulcheri M, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol. 2008;21(2):319-24.
35. Fry CM, Sanders TA. Vitamin D and risk of CVD: a review of the evidence. Proc Nutr Soc. 2015;74:1-13.
36. LeBlanc ES, Perrin N, Johnson JD, Ballatore A, Hillier T. Over-the-counter and compounded vitamin d: Is potency what we expect? JAMA Internal Medicine. 2013;173(7):585-6.
37. Chang C-K, Hayes RD, Perera G, Broadbent MTM, Fernandes AC, Lee WE, Hotopf M, Stewart R. Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London. PLoS One. 2011;6(5):1-6.
38. Stubbs B, De Hert M, Sepehry AA, Correll CU, Mitchell AJ, Soundy A, Detraux J, Vancampfort D. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand. 2014;130(6):470-86.
39. Meaney AM, Smith S, Howes OD, O'brien M, Murray RM, O'keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004;184(6):503-8.
40. Howes OD, Wheeler MJ, Meaney AM, O'Keane V, Fogelman I, Blake G, Murray RM, Smith S. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J Clin Psychopharmacol. 2005;25(3):259-61.
41. Stubbs B, Gaughran F, Mitchell AJ, De Hert M, Farmer R, Soundy A, Rosenbaum S, Vancampfort D. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):126-33.
42. Schneider B, Weber B, Frensch A, Stein J, Fritz J. Vitamin D in schizophrenia, major depression and alcoholism. J Neural Transm. 2000;107(7):839-42.
43. Hypponen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr. 2007;85(3):860-8.
44. Ruston DHJ, Henderson L, Gregory J. Vol 4. : The National Diet and Nutrition Survey: adults aged 19 to 64 years. Nutritional status (anthropometry and blood analytes), blood pressure and physical activity. In: Office for National Statistics, editor. The Stationery Office. London, United Kingdom: Office for National Statistics; 2004.
45. Belvederi Murri M, Respino M, Masotti M, Innamorati M, Mondelli V, Pariante C, Amore M. Vitamin D and psychosis: mini meta-analysis. Schizophr Res. 2013;150(1):235-9.
46. Farrell C-JL, Martin S, McWhinney B, Straub I, Williams P, Herrmann M. State-of-the-Art Vitamin D Assays: A Comparison of Automated Immunoassays with Liquid Chromatography-Tandem Mass Spectrometry Methods. Clin Chem. 2012;58(3):531-42.
47. Manson JE, Bassuk SS. Vitamin D research and clinical practice: at a crossroads. JAMA. 2015;313(13):1311-2.
48. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-8.
49. McGrath J. Is it time to trial vitamin D supplements for the prevention of schizophrenia? Acta Psychiatr Scand. 2010;121:321-4.